Adrenocortical Carcinoma Treatment Market - Global
Industry Insights, Trends, Outlook, and Opportunity
Analysis, 2018-2026
Adrenocortical carcinoma is a rare cancer affecting the outer layer of the adrenal glands, which
are responsible for producing certain hormones and maintaining optimum blood pressure levels.
Adrenocortical carcinoma is relatively frequent in children compared to other cancers, although
the cancer may also affect adults. The most common symptoms of adrenocortical carcinoma
include abdominal pain, hypertension, weight gain, and frequent urination, which are mainly
caused due to tumors causing excess secretion of hormones from the adrenal glands. Mitotane is
the only drug approved by the U.S. Food and Drug Administration (FDA) and European
Medicine Executive Agency (EMEA) for treatment of metastatic adrenocortical carcinoma.
According to the study by HealthLine Media, 2017, about 5-10% of the adrenal tumors are
malignant. Diagnosis of adrenocortical carcinoma is based on urine tests, dexamethasone
suppression test for detecting abnormal levels of cortisol, which is the hormone released by the
adrenal glands. Also, a wide number of imaging devices are used for diagnoses of the disease,
which includes CT scan, MRI, PET scan, and MIBG Scan, thus aiding for faster disease
identification that aids the doctors to decide for further treatments.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/1551
Adrenocortical Carcinoma Treatment Market: Market Dynamics
Increasing incidence of adrenocortical carcinoma associated with genetic disorders is a major
factor augmenting growth of the adrenocortical carcinoma treatment market. According to the
Journal of Clinical Endocrinology & Metabolism, 2013, the peak incidence of adrenocortical
carcinoma ranges between 40-50 years, where women are 55–60% more likely to get affected
with a ratio of ratio 1.5:1. The study also states that adrenocortical carcinoma is a rare and
highly aggressive malignancy with an annual incidence of 0.05–0.2% or 1-2 cases per million
population globally. Also, inherited disorders such as Li-Fraumeni syndrome (LFS), Beckwith-
Wiedemann syndrome (BWS), and Carney complex are linked with increasing incidence of
adrenocortical carcinoma. According to the survey by Endocrine Society, 2014, adrenocortical